New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 30, 2013
10:55 EDTFDX, FDX, LLY, LLYSenate Finance Committee to hold a hearing
The Committee holds a hearing entitled, "Transatlantic Trade and Investment Partnership: Achieving the Potential". Participants include Executive Vice President Ducker of FedEx (FDX) and Senior Vice President Ricks of Eli Lilly (LLY) at the hearing being held on October 30 at 11 am. Webcast Link
News For FDX;LLY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 21, 2015
07:37 EDTLLYPfizer replaces AbbVie as top global pharma pick at Jefferies
Subscribe for More Information
May 19, 2015
07:22 EDTFDXUPS having success with pickup points, WSJ says
Driven by the increase in e-commerce deliveries, UPS (UPS) has been combatting failed deliveries by using package pickup points, called UPS Access Points, like local drug stores, reports the Wall Street Journal. As a result UPS, FedEx (FDX), and DHL are investing in new systems aimed at having e-commerce customers collect orders from these pickup points, the Journal adds. Reference Link
May 15, 2015
12:13 EDTFDXThird Point gives quarterly update on stakes
NEW STAKES: Yum! Brands (YUM), NXP Semiconductors (NXPI), FedEx (FDX), McKesson (MCK), and J M Smucker (SJM). INCREASED STAKES: Actavis (ACT), Roper Technologies (ROP), Delta Air Lines (DAL), and FleetCor Technologies (FLT). DECREASED STAKES: Ally Financial (ALLY), Amgen (AMGN), Phillips 66 (PSX), eBay (EBAY), and Anheuser Busch Inbev SA (BUD). LIQUIDATED STAKES: Alibaba Group (BABA), Citigroup (C), EMC Corporation (EMC), Anglo American (AAL), and Williams Companies (WMB).
12:07 EDTFDXThird Point reports new stakes in Yum! Brands, FedEx, McKesson
06:33 EDTFDXJudge denies FedEx motion on drug charges, Reuters says
A judge denied FedEx's motion to dismiss charges that it was involved in distributing controlled substances, according to Reuters. The company is accused by the Justice Department of shipping packages from illegal online pharmacies, the news service stated. Reference Link
May 14, 2015
09:22 EDTLLYLeerink pharma/biotech analysts hold an analyst/industry conference call
Subscribe for More Information
07:44 EDTLLYInternational Headache Society to hold a conference
17th Congress of the International Headache Society is being held in Valencia, Spain on May 14-17.
06:04 EDTLLYEli Lilly, Sanford-Burnham to investigate immunological therapies
Subscribe for More Information
May 13, 2015
05:35 EDTFDXFedEx provides update on offer to acquire TNT Express
Subscribe for More Information
May 12, 2015
07:37 EDTFDXOppenheimer to hold a conference
10th Annual Industrial Growth Conference is being held in New York on May 12-13 with webcasted company presentations to begin on May 12 at 8:15 am; not all company presentations may be webcasted. Webcast Link
May 11, 2015
15:19 EDTLLYEli Lilly, BioNTech enter into research collaboration
Eli Lilly and BioNTech announced they have entered into a research collaboration to discover novel cancer immunotherapies. The companies will seek to use the power of the body's own immune system to attack cancer cells and create possible new treatment options for cancer patients. Leveraging the scientific expertise between the two organizations, Lilly and BioNTech will collaborate to identify and validate novel tumor targets and their corresponding T cell receptors in one or more types of cancer. These tumor targets and TCRs may then be engineered and developed into potent and selective cancer therapies. Under the terms of the agreement, BioNTech will receive a $30M signing fee. For each potential medicine, BioNTech could receive over $300M in development, regulatory and commercial milestones. If successfully commercialized, BioNTech would also be eligible for tiered royalty payments up to double-digits. In addition, subject to the terms of the agreement, Lilly will make a $30M equity investment in BioNTech's subsidiary, Cell & Gene Therapies GmbH, which specializes in the research and development of TCR and chimeric antigen receptor immunotherapeutics. Further financial terms were not disclosed.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use